Melanoma
Conditions
Keywords
Immuno-PET, Ipilimumab, Immunotherapy
Brief summary
Rationale: Ipilimumab, a monoclonal antibody targeting CTLA-4, is approved for the treatment of metastatic melanoma and significantly increases median overall survival. However, use of this drug is associated with immune related adverse events (IRAEs) like colitis, hepatitis, dermatitis, alveolitis and hypophysitis in 10-40% of the patients. In general IRAEs are manageable by cessation of ipilimumab in combination with treatment with corticosteroids or TNF-alpha blockade but they can be severe or even life-threatening. In addition, treatment with ipilimumab is expensive. Because of the high costs and the potential serious toxicity of ipilimumab, it is of great importance to identify biomarkers that correlate with clinical activity and can be used to select patients that will benefit from CTLA-4 blockade therapy. The investigators hypothesize that differences in response to treatment with ipilimumab are due to variability in the pharmacodynamics and -kinetics of the antibody. It is hypothesized that patients who do not respond to treatment with ipilimumab have lower drug levels in tumor tissues as compared to patients with a good response to therapy. In addition, the investigators hypothesize that IRAEs are associated with high drug levels in the affected tissue. To visualize molecular interactions a novel technique is used in which positron emission tomography (PET) is combined with labeled monoclonal antibodies. Because ipilimumab induces activation of T-lymphocytes it is hypothesized that uptake of 89Zr-ipilimumab in tumor lesions and normal tissue is different (i.e. higher) after the second administration of ipilimumab (3 weeks after first injection). Therefore immuno-PET scans will be performed after the first and after the second injection of ipilimumab. Objective: Part one: The primary objective is: 1\. To assess uptake (visual and quantitative) of 89Zr-ipilimumab in tumor lesions and biodistribution at two timepoints (at start of ipilimumab therapy and after the second injection 3 weeks later). The secondary objectives are: 1. To determine the correlation between tumor targeting of ipilimumab and response to therapy. 2. To assess uptake (visual and quantitative) of 89Zr-ipilimumab in normal tissues. 3. To determine de correlation between organ targeting and toxicity
Detailed description
see above
Interventions
BIOLOGICAL89Zirconium-labeled ipilimumab
Metastatic melanoma patients, who are treated with ipilimumab (3 mg/kg), will be infused with 89Zr-labeled ipilimumab within 2 hours after injection of the first and second standard ipilimumab doses. Peripheral blood mononuclear cells (PBMCs) will be collected for immunomonitoring.
Sponsors
Bristol-Myers Squibb
Amsterdam UMC, location VUmc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Advanced/metastatic melanoma. * Scheduled for treatment with ipilimumab. * Age ≥ 18 years. * Histological or cytological documentation of cancer is required. * WHO Performance Status of 0 or 1. * At least 1 measurable lesion. * Signed informed consent must be obtained prior to any study procedures. * Patients must be able to adhere to the study appointments and other protocol requirements.
Exclusion criteria
* Previous exposure to ipilimumab. * Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start treatment. Both men and women enrolled in this trial must agree to use adequate barrier birth control measures (e.g. cervical cap, condom and diaphragm) during the course of the trial. Oral birth control methods alone will not be considered adequate on this study, because of the potential pharmacokinetic interaction between study drug and oral contraceptives. Concomitant use of oral and barrier contraceptives is advised. Contraception is necessary for at least 6 months after receiving study drug. * Concurrent anticancer chemotherapy, immunotherapy or investigational drug therapy during the study or within 4 weeks after starting the study drug. * Radiotherapy of target lesions during study or within 4 weeks after starting the study drug. Palliative radiotherapy will be allowed. * Major surgery within 28 days of start of study drug. * Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results. * Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The detection of 89Zr-ipilimumab in tumor lesions | 3 weeks | The detection (visual and quantitative) of 89Zr-ipilimumab in tumor lesions (the short axis diameter of a measurable tumor lesion is ≥1 cm. The five largest lesions will be used for evaluation). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The quantitative detection of 89Zr-ipilimumab in normal tissue | 3 weeks | The quantitative detection of 89Zr-ipilimumab in normal tissue after the first injection of ipilimumab and after the second injection 3 weeks later. Quantitative: The % uptake (of total injected) 89Zr-ipilimumab in normal tissue, measured in VOI's. |
| Comparison between uptake of 89Zr-ipilimumab | 3 weeks | Comparison between uptake (SUVmean and SUVpeak) of 89Zr-ipilimumab after the first injection of ipilimumab and after the second injection 3 weeks later. |
| Clinical outcome (response) | Every 12 weeks, from date of starting therapy until the date of first documented progression or date of death from any cause, whichever came first. Assessed through study completion, an average of 1 year | Response after starting therapy with ipilimumab at 12 and 24 weeks and every 12 weeks thereafter |
| Clinical outcome (survival) | Through study completion, an average of 1 year | Overall survival |
| The visual detection of 89Zr-ipilimumab in normal tissue | 3 weeks | The visual detection of 89Zr-ipilimumab in normal tissue after the first injection of ipilimumab and after the second injection 3 weeks later. Visual: Description of the biodistribution. |
| Pharmacokinetics of 89Zr-ipilimumab | 144 hours after first injection of 89Zr-ipilimumab | Pharmacokinetics of 89Zr-ipilimumab. The concentration of ipilimumab in blood samples will be measured at t = 5, 30, 60, 120 minutes and 72, 144 hours after injection of 89Zr-ipilimumab in the first three patients. |
| CTLA-4+CD4+ expression of PBMCs | Before start of ipilimumab and during treatment, up to 11 weeks | — |
| Immunohistochemical analysis | 3 weeks | Immunohistochemical analysis (% of tissue with inflammatory infiltrate and characterization of intratumoral T-lymphocytes (CD4, CD8, HLA-DR, FOX-P3, CTLA-4) of tumor biopsy |
| Side effects | Until 30 days after the last immuno-PET scan | * Adverse events using Common Terminology Criteria Adverse Events, version 4.0 (CTCAE 4.0) * Correlation between side effects of ipilimumab and uptake of 89Zr-ipilimumab in normal tissue |
Countries
Netherlands
Contacts
Primary ContactJelle Arts
Backup ContactAlfonsus JM van den Eertwegh, Prof.dr.
Outcome results
None listed